'Cancer Drug Market Will Reach $75 Billion in 2012' visiongain Report Predicts

LONDON, February 27, 2012 /PRNewswire/ --

http://www.visiongain.com/Report/770/Leading-Anti-Cancer-Drugs-and-Associated-Market-2012-2022

A new report by visiongain predicts that the world market for cancer-treating drugs will reach $75 billion for 2012. That revenue forecast appears in Leading Anti-Cancer Drugs and Associated Market 2012-2022, published in February 2012. Visiongain is a business information provider based in London, UK.

The new study predicts that overall revenues for anti-cancer treatments will increase strongly from 2012 to 2022. Individual drugs will benefit too. Roche will continue to be the leading company in the cancer-treating drugs market throughout the study's forecast period. Through emerging technologies and increasing demand in developed and developing countries, the future of cancer treatments holds great promise. That revenue growth will be mainly owing to the worldwide increase in cancer incidence and prevalence. New opportunities for cancer treatment exist, with high sales likely from many drugs - small-molecule products and biological agents (biologicals) - to 2022. Also, R&D pipelines in oncology are strong, including those for monoclonal antibodies (MAbs).

The visiongain pharmaceutical industry analyst at visiongain, said, "Although oncology is one of the most researched areas of medicine, there remain un-met and under-met treatment needs. There is a need for well targeted therapies with better safety and efficacy. It is crucial that anti-cancer drugs have minimal side effects, so that the quality of patients' lives can be enhanced. Pharma companies will further explore this field, making therapeutic progress this decade. In particular, companion diagnostic tests with drugs will help in cancer treatment, giving more-personalised, better-targeted medicine."

Visiongain's report provides revenue forecasts to 2022 at world market, submarket, product and national level. It forecasts world sales for the following submarkets:

• Traditional antineoplastic agents
• Novel antineoplastic agents
• Hormone therapies
• Immunotherapies
• Other agents.

That investigation forecasts sales of 25 leading drugs in the anti-cancer treatment market, including Avastin, Rituxan, Herceptin and Glivec/Gleevec. The study also assesses eight recently approved drugs. Research, data and analyses cover activities of Roche, Novartis, AstraZeneca, Eli Lilly, Celgene and other pharmaceutical companies.

The analysis includes researching the oncology R&D pipeline, interviewing authorities on the industry and forecasting revenues in leading national markets. Countries analysed are the US, Japan, the EU5 and BRIC countries. Leading Anti-Cancer Drugs and Associated Market 2012-2022 adds to visiongain's range of analytical reports on industries and markets in healthcare.

To view sample pages of the report please click on:

http://www.visiongain.com/Report/770/Leading-Anti-Cancer-Drugs-and-Associated-Market-2012-2022

For an exec summary please email Sara Peerun on:  sara.peerun@visiongainglobal.com

Companies listed in this critical report include:

AB Sciences USA
Abbott Laboratories
Abraxis BioScience
Active Biotech
Advaxis
Aeterna Zentaris
Agenus
Algeta
Allergan
Ambit Biosciences
Amgen
APP Pharmaceuticals
ArQule
Array BioPharma
Astellas Pharma
AstraZeneca
AVEO Pharmaceuticals
Bayer HealthCare
Baylor College of Medicine
BioCancell Therapeutics
Biogen Idec
Bioniche Life Sciences
BioVEX
BiPar Sciences
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
Cancer Advances
Celgene
Celldex Therapeutics
Chugai
Cipla
Cougar Biotechnology
Cyclacel Pharmaceuticals
Daiichi Sankyo
Dako
Dan L. Duncan Cancer Center
Dendreon
Dr. Reddy's Laboratories
Eisai
Eleison Pharmaceuticals
Eli Lilly
EMD Serono
Endo Pharmaceuticals
European Medicines Agency (EMA)
Exelixis
Food and Drug Administration (US FDA)
GE Healthcare
Genentech
GenMab
Genta
Genzyme
GlaxoSmithKline (GSK)
Hospira
ImClone Systems
Inovio Pharmaceuticals
International Cancer Genome Consortium
Janssen-Cilag
Johnson & Johnson (J&J)
Keryx Biopharmaceuticals
Lester and Sue Smith Breast Center, Baylor College of Medicine
Lpath
Marshall Edwards
MedImmune
Medivation
Menarini
Merck & Co.
Merck Serono
Micromet
Millennium Pharmaceuticals
Mylan
National Health Service (UK)
National Institute for Health and Clinical Excellence (NICE, UK)
Nektar Therapeutics
Novartis
OncoGenex Pharmaceuticals
Onconova Therapeutics
Onyx Pharmaceuticals
OSI Pharmaceuticals
Otsuka
Oxford University
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Plexxikon
Progen Pharmaceuticals
Proteolix
Puma Biotechnology
Radient
RBC Capital Markets
Regeneron
Roche
Sandoz
Sanofi
Seattle Genetics
Spectrum Pharmaceuticals
Sunesis Pharmaceuticals
Syndax Pharmaceuticals
Tactic Pharma
Taiho Pharma USA
Takeda
TargeGen
TenX Biopharma
Teva Pharmaceutical Industries
Transgene
UCB
United Therapeutics
Vaccine Company
Wellstat Biologics
Wilex
World Health Organization (WHO)
Yaupon Therapeutics
Zenyaku Kogyo
ZIOPHARM Oncology
Zor Pharmaceuticals

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100